FDA issues hold on much-debated Avandia study

Jul 21, 2010 By MATTHEW PERRONE , AP Business Writer
In this June 30, 2010 file photo, a pharmacist holds a bottle of Avandia pills at Maximart Pharmacy in Palo Alto, Calif. Federal health officials say new patients should not be enrolled in a study of GlaxoSmithKline's controversial diabetes pill Avandia, after experts last week said the drug increases heart risks. (AP Photo/Paul Sakuma, file)

(AP) -- Federal health officials are barring new patients from enrolling in a safety study of GlaxoSmithKline's controversial diabetes pill Avandia, a week after a panel of experts ruled that the drug increases heart risks.

The said it issued a "partial clinical hold" on the study to update researchers on the latest concerns about , which has been under scrutiny since 2007.

Last week a panel of experts voted that the drug appears to increase heart risks, but they ultimately voted to leave the drug on the market because the evidence was not definitive.

The FDA is currently reviewing the panel's opinions and deciding what action to take.

said in a statement it would halt recruitment for the so-called TIDE trial and update the study's chief investigators on last week's meeting. Patients already in the study will be permitted to continue participating.

The London-based drugmaker agreed to conduct the trial in 2007, after safety questions about Avandia were first publicized.

The TIDE study is designed to give a definitive picture of whether Avandia's heart risks are greater than its chief competitor Actos.

Last week, the FDA's panel of outside advisers voted 20-10 that the trial should continue if Avandia stays on the market.

However, Avandia's critics have argued that the trial is unethical since current evidence already shows Avandia is riskier than Actos, which is made by Japan-based Takeda Pharmaceuticals.

"It's the ethically correct thing to do," said Dr. Steven Nissen, chairman of at the Cleveland Clinic. "It was the only decision the FDA could have made."

Nissen first drew attention to Avandia's risks in a 2007 medical journal article estimating the drug increases risk by 43 percent. He noted that the FDA's advisory panel specifically voted last week that Avandia increased risk of heart attacks more than Actos.

"I still think there's a very good chance that the FDA will decide to remove Avandia from the market," Nissen said.

The TIDE study is supposed to enroll 16,000 patients, though safety concerns surrounding Avandia have slowed recruitment. Glaxo reported last week that just 1,100 patients have volunteered for the study.

The FDA first approved Avandia in 1999 and it quickly became the top-selling diabetes pill in the world. However, U.S. sales have plummeted from $2.2 billion in 2006 to $520 million last year as safety concerns swirled around the drug.

The drug works by increasing the body's sensitivity to insulin, a key protein needed for digestion that diabetics don't adequately produce.

The FDA added a black box warning to the drug in 2007. New studies on the drug's safety combined with pressure from safety advocates has prompted the agency to take another look at the drug.

The FDA is expected to make a decision on whether to keep the drug on the market in coming months.

Explore further: FDA approves AbbVie combo hepatitis C treatment

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA panel: Diabetes drug should stay on market

Jul 14, 2010

(AP) -- A majority of federal health experts voted Wednesday to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack.

FDA review spotlights heart risk of diabetes pill

Jul 09, 2010

(AP) -- A review by federal health scientists reinforces potential ties between the diabetes pill Avandia and heart attack and death, opening the door for government action, including a possible withdrawal of the once blockbuster ...

Glaxo defends handling of Avandia heart risks

Feb 24, 2010

(AP) -- GlaxoSmithKline said Wednesday a Senate report criticizing its handling of heart risks with its diabetes drug Avandia "mischaracterizes and distorts" the company's record.

Senate report: Avandia maker knew of cardiac risks

Feb 22, 2010

(AP) -- A Senate report said Saturday that drug maker GlaxoSmithKline knew of possible heart attack risks tied to Avandia, its diabetes medication, years before such evidence became public.

Diabetes drug risks reported ahead of FDA hearing

Jun 28, 2010

(AP) -- A new study led by a federal drug safety expert ties the controversial diabetes drug Avandia to a higher risk of heart problems, strokes and deaths in older adults, and says it is more dangerous than a rival drug, ...

Recommended for you

FDA OKs Cubist antibiotic for serious infections

26 minutes ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.